With our most popular mining stocks fully or over-valued and not appearing to offer much joy, here are four other big miners that appear to be offering good total-return value right now.
At $4.12, is South32 worth buying for reasons other than simply having graduated to the S&P/ASX 20 index? Here’s my view…
Here are four of what I think are highly attractive oil and gas opportunities on the ASX.
In my article today I want to look at the devices part of the biotech world: here are 3 examples of some of the wonderful technology coming out of Australia and being taken to a global market.
Companies bringing new copper production to the market over the next few years can expect to be looked upon very favourably by the market. Here are what I think are 3 outstanding prospects on the ASX.
Can there possibly be good buying in single-digit share prices? I’ve been trawling through the ASX-listed population looking for this kind of situation, and here are two single-digit share prices that I think fit the bill
The fact of biotech investing is that the share prices are at the mercy of news flow from drug trial results, partnerships with bigger companies, regulatory interactions and a wide range of other events that can point to the increased – or decreased – likelihood of the drug, medical device or diagnostic test ever reaching the market.
There’s no shortage of world-class innovation coming out of our neighbour across the ditch. Here are three Kiwi stocks that I think are global standouts in their fields — and each of these, for various reasons, looks to be alluringly cheap right now.
Here are three of the best (non-Kiwi) foreign listings: Block (Afterpay), Resmed and Zimplats.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.